Cargando…

Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport

HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Quizon, Pamela M., Yuan, Yaxia, Zhu, Yike, Zhou, Yi, Strauss, Matthew J., Sun, Wei-Lun, Zhan, Chang-Guo, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329121/
https://www.ncbi.nlm.nih.gov/pubmed/33537927
http://dx.doi.org/10.1007/s11481-021-09984-5
_version_ 1783732434060181504
author Quizon, Pamela M.
Yuan, Yaxia
Zhu, Yike
Zhou, Yi
Strauss, Matthew J.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
author_facet Quizon, Pamela M.
Yuan, Yaxia
Zhu, Yike
Zhou, Yi
Strauss, Matthew J.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
author_sort Quizon, Pamela M.
collection PubMed
description HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport. Compared to wild-type hDAT, the maximal velocity (V(max)) of [(3)H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L. Recombinant TatR(1 − 86) inhibited dopamine uptake in wild-type hDAT, which was attenuated in either DAT mutants (D206L, D206L/H547A, and Y88F/D206L/H547A) or mutated TatR(1 − 86) (K19A and C22G), demonstrating perturbed Tat-DAT interaction. Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [(3)H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP(+) efflux in D206L/H547A. H547A-induced outward-open transport conformational state was further validated by enhanced accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of an inserted cysteine (I159C) on a hDAT background.. Furthermore, H547A displayed an increase in palmitoylation inhibitor-induced inhibition of dopamine uptake relative to wide-type hDAT, indicating a change in basal palmitoylation in H547A. These results demonstrate that Y88F, D206L, and H547A attenuate Tat inhibition while preserving DA uptake, providing insights into identifying targets for improving DAT-mediated dopaminergic dysregulation. GRAPHICAL ABSTRACT: HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction. Key hDAT residues D-H547, D-Y88, and D-D206 are predicted to be involved in the HIV-1 Tat-DAT binding. Mutating these residues attenuates this inhibitory effect by disrupting the Tat-hDAT interaction [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-021-09984-5.
format Online
Article
Text
id pubmed-8329121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83291212021-12-29 Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport Quizon, Pamela M. Yuan, Yaxia Zhu, Yike Zhou, Yi Strauss, Matthew J. Sun, Wei-Lun Zhan, Chang-Guo Zhu, Jun J Neuroimmune Pharmacol Original Article HIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport. Compared to wild-type hDAT, the maximal velocity (V(max)) of [(3)H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L. Recombinant TatR(1 − 86) inhibited dopamine uptake in wild-type hDAT, which was attenuated in either DAT mutants (D206L, D206L/H547A, and Y88F/D206L/H547A) or mutated TatR(1 − 86) (K19A and C22G), demonstrating perturbed Tat-DAT interaction. Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [(3)H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP(+) efflux in D206L/H547A. H547A-induced outward-open transport conformational state was further validated by enhanced accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of an inserted cysteine (I159C) on a hDAT background.. Furthermore, H547A displayed an increase in palmitoylation inhibitor-induced inhibition of dopamine uptake relative to wide-type hDAT, indicating a change in basal palmitoylation in H547A. These results demonstrate that Y88F, D206L, and H547A attenuate Tat inhibition while preserving DA uptake, providing insights into identifying targets for improving DAT-mediated dopaminergic dysregulation. GRAPHICAL ABSTRACT: HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction. Key hDAT residues D-H547, D-Y88, and D-D206 are predicted to be involved in the HIV-1 Tat-DAT binding. Mutating these residues attenuates this inhibitory effect by disrupting the Tat-hDAT interaction [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-021-09984-5. Springer US 2021-02-03 2021 /pmc/articles/PMC8329121/ /pubmed/33537927 http://dx.doi.org/10.1007/s11481-021-09984-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Quizon, Pamela M.
Yuan, Yaxia
Zhu, Yike
Zhou, Yi
Strauss, Matthew J.
Sun, Wei-Lun
Zhan, Chang-Guo
Zhu, Jun
Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title_full Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title_fullStr Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title_full_unstemmed Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title_short Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport
title_sort mutations of human dopaminetransporter at tyrosine88, aspartic acid206, and histidine547 influence basal and hiv-1 tat‐inhibited dopamine transport
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329121/
https://www.ncbi.nlm.nih.gov/pubmed/33537927
http://dx.doi.org/10.1007/s11481-021-09984-5
work_keys_str_mv AT quizonpamelam mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT yuanyaxia mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT zhuyike mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT zhouyi mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT straussmatthewj mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT sunweilun mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT zhanchangguo mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport
AT zhujun mutationsofhumandopaminetransporterattyrosine88asparticacid206andhistidine547influencebasalandhiv1tatinhibiteddopaminetransport